Owkin, Genmab A/S to explore cancer patient profiles for treatment improvements
Today, Owkin announced a research agreement with Genmab A/S (Nasdaq: GMAB), an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics to fight against cancer and other serious diseases, to better understand the complex biological profiles of cancer patients.
Owkin will apply state-of-the-art machine learning to multimodal patient data, accessed through their federated research network of leading academic centers and medical experts to improve patient outcomes by analysing certain patient subgroups’ response to treatments in an effort to evaluate the medical impact of Genmab’s clinical assets, including trial design and patient selection.
The research agreement will focus on patients diagnosed with certain types of cancers.
Financial terms are not disclosed but include an upfront payment and R&D funding.
About Owkin
Owkin is an agentic AI company pioneering Biological Artificial Superintelligence to solve problems in biology where human researchers alone have failed.
Owkin builds K Pro - an AI scientist for pharmaceutical research and strategic decision-making. K Pro orchestrates a suite of AI skills and tools to decode complex biology, accelerate research, and dramatically increase productivity.
K Pro is built on Owkin’s unrivalled multimodal patient data network, state-of-the-art AI for biology and decade of of experience working with pharmaceutical partners.
